DK1132086T3 - Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt - Google Patents

Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Info

Publication number
DK1132086T3
DK1132086T3 DK01300690T DK01300690T DK1132086T3 DK 1132086 T3 DK1132086 T3 DK 1132086T3 DK 01300690 T DK01300690 T DK 01300690T DK 01300690 T DK01300690 T DK 01300690T DK 1132086 T3 DK1132086 T3 DK 1132086T3
Authority
DK
Denmark
Prior art keywords
acute
agonists
renal failure
prostaglandin
chronic renal
Prior art date
Application number
DK01300690T
Other languages
Danish (da)
English (en)
Inventor
David Duane Thompson
Vishwas Madhav Paralkar
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1132086T3 publication Critical patent/DK1132086T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
DK01300690T 2000-01-31 2001-01-25 Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt DK1132086T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17896800P 2000-01-31 2000-01-31

Publications (1)

Publication Number Publication Date
DK1132086T3 true DK1132086T3 (da) 2006-08-28

Family

ID=22654657

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01300690T DK1132086T3 (da) 2000-01-31 2001-01-25 Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt

Country Status (18)

Country Link
US (1) US6610719B2 (xx)
EP (1) EP1132086B1 (xx)
JP (2) JP3839261B2 (xx)
KR (1) KR100419684B1 (xx)
AT (1) ATE327751T1 (xx)
AU (1) AU774569B2 (xx)
CA (1) CA2332687A1 (xx)
CO (1) CO5261529A1 (xx)
CY (1) CY1105299T1 (xx)
DE (1) DE60120007T2 (xx)
DK (1) DK1132086T3 (xx)
ES (1) ES2263557T3 (xx)
HU (1) HUP0100495A3 (xx)
IL (1) IL141120A0 (xx)
NZ (1) NZ509632A (xx)
PE (1) PE20011048A1 (xx)
PT (1) PT1132086E (xx)
ZA (1) ZA200100827B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024647A1 (fr) * 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine
CN1476429A (zh) 2000-11-27 2004-02-18 �Ʒ� 治疗骨质疏松的ep4受体选择性激动剂
BR0211167A (pt) * 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides
WO2003009872A1 (en) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
AU2002340282B2 (en) 2001-10-23 2007-08-09 Merck Serono Sa Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
WO2003074483A1 (fr) 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif
MXPA04009036A (es) * 2002-03-18 2005-01-25 Pfizer Prod Inc Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular.
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2488001C (en) * 2002-06-06 2011-03-22 Merck Frosst Canada & Co. 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
CA2483555A1 (en) * 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
FI20030015A0 (fi) * 2003-01-03 2003-01-03 Orion Corp Menetelmä munuaisten vajaatoiminnan hoitamiseksi
EP1586564B1 (en) * 2003-01-21 2012-11-28 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medicinal uses thereof
GB0302094D0 (en) * 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US20080306155A1 (en) * 2004-09-16 2008-12-11 Roman Richard J Method for treating renal disease
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
EP3533445A1 (en) 2009-03-19 2019-09-04 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
KR101967868B1 (ko) 2010-06-17 2019-08-19 닛토덴코 가부시키가이샤 신장 섬유증 치료 물질
CA2807944C (en) 2010-08-12 2020-02-18 Fate Therapeutics, Inc. Improved hematopoietic stem and progenitor cell therapy
RU2627842C2 (ru) * 2011-08-02 2017-08-14 Оно Фармасьютикал Ко., Лтд. Средство для улучшения диастолической функции левого желудочка
KR102011532B1 (ko) 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
EP3381456A1 (en) 2011-12-02 2018-10-03 Fate Therapeutics, Inc. Improved methods for treating ischemia
CA2857640C (en) 2011-12-02 2021-11-16 Fate Therapeutics, Inc. Enhanced stem cell composition
US20150272874A1 (en) 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
JP6449166B2 (ja) 2013-10-15 2019-01-09 小野薬品工業株式会社 薬剤溶出性ステントグラフト
JP6713147B2 (ja) 2014-01-24 2020-06-24 アーエム−ファルマ ベー．フェー．ＡＭ−Ｐｈａｒｍａ Ｂ．Ｖ． アルカリホスファターゼの下流プロセシング
KR102166110B1 (ko) 2014-01-24 2020-10-16 에이엠-파마 비.브이. 키메라 알칼리성 포스파타제-유사 단백질
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
EP3250682A4 (en) 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
CN107849072B (zh) 2015-06-12 2020-12-15 西蒙弗雷泽大学 酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
EP3324982A4 (en) 2015-07-21 2019-01-09 The Children's Medical Center Corporation HEMATOPOIETIC STEM CELLS EXPRESSING PD-L1 AND USES
WO2017139561A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
AU2017217813B2 (en) 2016-02-12 2023-08-03 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
US20230193212A1 (en) 2020-05-06 2023-06-22 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066692A (en) 1972-10-30 1978-01-03 Merck & Co., Inc. 11,12-secoprostaglandins
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
US3991087A (en) 1973-12-13 1976-11-09 Merck & Co., Inc. 8-Halo-11,12-secoprostaglandins
SE7414770L (xx) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
SE423813B (sv) * 1976-08-06 1982-06-07 Pfizer Forfarande for framstellning av 1,5-disubstituerade pyrrolidoner med terapeutiska egenskaper
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4112236A (en) 1977-04-04 1978-09-05 Merck & Co., Inc. Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US5605814A (en) 1993-08-31 1997-02-25 Merck Frosst Canada Inc. DNA encoding human prostaglandin receptor EP2
US5716835A (en) 1994-05-05 1998-02-10 Allergan, Inc. Nucleic acid encoding a novel human EP prostaglandin receptor
US5807895A (en) * 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AU7349298A (en) 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
US6124314A (en) 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6586468B1 (en) * 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
CA2332427A1 (en) * 1999-03-16 2000-09-21 Toray Industries, Inc. Prostaglandin ep4 receptor agonist and treatment method

Also Published As

Publication number Publication date
EP1132086A3 (en) 2002-01-09
AU774569B2 (en) 2004-07-01
ES2263557T3 (es) 2006-12-16
US6610719B2 (en) 2003-08-26
NZ509632A (en) 2003-01-31
PT1132086E (pt) 2006-09-29
HU0100495D0 (en) 2001-03-28
JP3839261B2 (ja) 2006-11-01
IL141120A0 (en) 2002-02-10
ZA200100827B (en) 2002-07-30
KR100419684B1 (ko) 2004-02-21
DE60120007T2 (de) 2006-11-16
HUP0100495A3 (en) 2003-12-29
PE20011048A1 (es) 2001-10-19
CA2332687A1 (en) 2001-07-31
ATE327751T1 (de) 2006-06-15
CY1105299T1 (el) 2010-03-03
JP2006182788A (ja) 2006-07-13
AU1672201A (en) 2001-08-02
EP1132086A2 (en) 2001-09-12
DE60120007D1 (de) 2006-07-06
US20010041729A1 (en) 2001-11-15
KR20010078209A (ko) 2001-08-20
JP2001233792A (ja) 2001-08-28
CO5261529A1 (es) 2003-03-31
HUP0100495A2 (en) 2002-10-28
EP1132086B1 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
DK1132086T3 (da) Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
DK1202724T3 (da) Fremgangsmåde til behandling af kronisk smerte under anvendelse af mek-inhibitorer
DK1542977T3 (da) 2,5-dioxoimidazolidin-4-ylacetamider og analoger som inhibitorer af metalloproteinase MMP12
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
NO20080612L (no) Immunokonjugatpreparater
DK2314319T3 (da) Sammensætninger til rensning af colon
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse
BRPI0516128A (pt) uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
DE60029242D1 (de) Arzneien zur begleitenden behandlung von glaukomen
EA200300988A1 (ru) Производные фенил-гетероциклильных эфиров в качестве ингибиторов обратного захвата серотонина
DE602005010258D1 (de) Behandlung von ballastwasser
ATE443044T1 (de) Tace inhibitoren
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction
DK1301475T3 (da) Arylsulfonamider, som serotoninantagonist til behandling af obesitet
DK1642576T3 (da) Anvendelse af pyrrolderivater til at bekæmpe angst
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1513529T3 (da) Tredobbelte monoamin-genoptagelsesinhibitorer til behandling af kronisk smerte